MA54960A - Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine - Google Patents

Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine

Info

Publication number
MA54960A
MA54960A MA054960A MA54960A MA54960A MA 54960 A MA54960 A MA 54960A MA 054960 A MA054960 A MA 054960A MA 54960 A MA54960 A MA 54960A MA 54960 A MA54960 A MA 54960A
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyrimidine
amine derivative
amine
derivative
Prior art date
Application number
MA054960A
Other languages
English (en)
Inventor
Hirokazu Fuchida
Shoki Hara
Hidefumi Kasuga
Yu KOBAYAKAWA
Takashi Mizutani
Yoshio Ogino
Fuyuki Yamamoto
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA54960A publication Critical patent/MA54960A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054960A 2019-02-15 2020-02-14 Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine MA54960A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019025844 2019-02-15

Publications (1)

Publication Number Publication Date
MA54960A true MA54960A (fr) 2021-12-22

Family

ID=72044229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054960A MA54960A (fr) 2019-02-15 2020-02-14 Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine

Country Status (13)

Country Link
US (1) US11786534B2 (fr)
EP (1) EP3925669A4 (fr)
JP (1) JP6960064B2 (fr)
KR (1) KR102645237B1 (fr)
CN (1) CN113453764B (fr)
AU (1) AU2020221744B2 (fr)
BR (1) BR112021015813A2 (fr)
CA (1) CA3130049C (fr)
MA (1) MA54960A (fr)
MX (1) MX2021009752A (fr)
SG (1) SG11202108648TA (fr)
TW (1) TWI828861B (fr)
WO (1) WO2020166680A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023204304A1 (fr) * 2022-04-22 2023-10-26 大鵬薬品工業株式会社 Procédé de production d'un dérivé de 7h-pyrrolo[2,3-d]pyrimidine-4-amine
WO2023204303A1 (fr) * 2022-04-22 2023-10-26 大鵬薬品工業株式会社 Cristal de dérivé de 7h-pyrrolo[2,3-d]pyrimidine-4-amine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520028A (ja) * 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Igfr抑制剤および抗癌剤の併用
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2013118817A1 (fr) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 Composé de quinolyl pyrrolopyrimidine ou son sel
CN104854107A (zh) 2012-11-15 2015-08-19 药品循环公司 作为激酶抑制剂的吡咯并嘧啶化合物
JP6427599B2 (ja) 2014-05-19 2018-11-21 チャンスー ヘンルイ メディシン カンパニー,リミテッド チロシンキナーゼ阻害剤としての置換エチニルヘテロ二環式化合物
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20

Also Published As

Publication number Publication date
EP3925669A1 (fr) 2021-12-22
WO2020166680A1 (fr) 2020-08-20
CN113453764A (zh) 2021-09-28
JPWO2020166680A1 (ja) 2021-11-04
EP3925669A4 (fr) 2022-10-26
KR102645237B1 (ko) 2024-03-07
US11786534B2 (en) 2023-10-17
US20220160719A1 (en) 2022-05-26
TW202045509A (zh) 2020-12-16
BR112021015813A2 (pt) 2021-10-13
TWI828861B (zh) 2024-01-11
KR20210116598A (ko) 2021-09-27
SG11202108648TA (en) 2021-09-29
JP6960064B2 (ja) 2021-11-05
AU2020221744A1 (en) 2021-09-23
CA3130049C (fr) 2024-04-16
CA3130049A1 (fr) 2020-08-20
CN113453764B (zh) 2024-04-16
MX2021009752A (es) 2021-09-08
AU2020221744B2 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MA47500A (fr) Dérivés de pyrrolo [1,2-b]pyridazine
IL276802A (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidin-3-ones
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物
DK3523301T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
IL285315A (en) Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists
IL262673A (en) Pyrazolo[1,5-a]pyrimidine compound
EP3660019C0 (fr) 7h-pyrazolo[3,4-d]triazine-2-oxides en tant qu'explosifs
EP3196199A4 (fr) N-(pyrrolidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine substituée utilisée en tant qu'inhibiteur de la janus kinase
IL290445A (en) [4,2,1]triazolo[5,1-c]quinazoline-5-amines
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
HK1259613A1 (zh) 新型5h-吡咯並[2,3-d]嘧啶-6(7h)-酮衍生物
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
IL262711A (en) History of a [3,2,1]triazolo[5,4-d]pyrimidine with affinity for the type 2 cannabinoid receptor
MA54960A (fr) Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine
EP3475286A4 (fr) Utilisation des composés pyrrolo[2,3-d]pyridazin-4-ones et pyrazolo[3,4-d]pyridazin-4-ones substitués comme inhibiteurs de protéines kinases